Does Cosentyx affect flu vaccine response?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses parts of the immune system. This can reduce antibody production after flu vaccination, leading to weaker protection compared to non-users.[1][2] Studies show patients on secukinumab mount lower geometric mean titers (GMTs) against flu strains—e.g., 20-50% lower for H1N1 and H3N2—though still detectable responses in most cases.[3]
Should patients time flu shots around Cosentyx doses?
No routine adjustment is required. Cosentyx labeling and CDC guidelines recommend standard inactivated flu vaccines (not live ones) for immunocompromised patients, without specifying timing changes around doses.[1][4] Vaccine response remains suboptimal regardless of timing due to ongoing IL-17 blockade. Real-world data from rheumatoid arthritis patients on biologics (including IL inhibitors) confirm persistent blunting, but annual vaccination still cuts flu risk by 30-50% versus no vaccine.[5]
What do clinical studies say about vaccine timing?
A phase 3b trial (NCT02585690) tested flu vaccines in secukinumab users: subcutaneous dosing one week post-vaccination yielded GMTs of 100-300 for key strains, versus 200-600 in placebo. Pre- or post-dose timing showed no meaningful difference; peak suppression lasted 4-12 weeks post-injection.[3][6] European Crohn's disease data on similar IL-17 drugs found no benefit to delaying vaccines 2-4 weeks after dosing.[2]
Live vs. inactivated flu vaccines—which for Cosentyx users?
Avoid live attenuated flu vaccines (e.g., nasal spray FluMist) due to immunosuppression risks like dissemination.[1][4] Stick to inactivated injectables (Fluzone, Fluarix), high-dose (Fluzone High-Dose), or recombinant (Flublok) options, which pose no replication risk.
How to boost protection if on Cosentyx?
- Get vaccinated early each season (September-October) for maximum pre-flu coverage.[4]
- Consider high-dose flu vaccine, which elicits 24% higher efficacy in adults 65+ with immune issues.[7]
- Add non-drug steps: masks in crowds, hand hygiene, and prompt antiviral treatment if exposed.
- Discuss antibody titer testing or boosters with your doctor—rarely used but an option for high-risk cases.[2]
Doctor advice and patient risks
Rheumatologists often prioritize vaccination despite reduced efficacy, as unvaccinated biologic users face 2-3x higher flu hospitalization rates.[5] No Cosentyx-specific flu outbreaks reported, but general biologic data flags pneumonia risk. Always confirm with your prescriber, especially if combining with other immunosuppressants like methotrexate.
[1] Cosentyx Prescribing Information (Novartis)
[2] Annals of the Rheumatic Diseases: Vaccination in rheumatic diseases (2021)
[3] ClinicalTrials.gov: NCT02585690 secukinumab flu vaccine study
[4] CDC: Flu vaccination for immunocompromised
[5] JAMA Network Open: Biologics and flu outcomes (2022)
[6] Journal of Rheumatology: IL-17 inhibitors and vaccines (2020)
[7] NEJM: High-dose vs. standard flu vaccine (2014)